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Summnry-In three experiments, rats were injected once daily with 5.0 mg/kg apomorphine or vehicle and 
tested for locomotor activity for 10-14 days. In each experiment, apomorphine produced behavioral 
sensitization, characterized by a progressively greater increase in locomotor activity with each succeeding 
injection. On day 11 of testing, in an experiment designed to assess the synthesis of dopamine (DA), rats 
were injected with 5.0 mg/kg apomorphine or vehicle, followed by 100 mg/kg NSD-1015, an inhibitor of 
the enzyme /-aromatic amino acid decarboxylase. After administration of NSD-1015, concentrations of 
dihydroxyphenylalanine (DOPA) were determined in striatal and mesolimbic tissues by high performance 
liquid chromatography (HPLC) with electrochemical detection. The results revealed a significant decrease 
in accumulation of DOPA in both striatal and mesolimbic tissue after acute treatment with apomorphine. 
More important, chronic treatment with apomorphine prodiJced a significant increase in accumulation of 
DOPA in both areas. In subsequent experiments, rats on day 14 of testing were sacrificed for determination 
of levels of DA, 3,4-dihydroxyphenylacetic acid (DOPAC) or specific binding of [3H]spiperone in the 
striatum and mesolimbic region. Although levels of DOPAC were significantly reduced in the regions of 
the brain after an acute injection of apomorphine, chronic treatment with apomorphine did not 
significantly affect levels of DA, DO PAC or specific binding of [3H]spiperone. These findings suggest that 
the development of behavioral sensitization to apornorphine may be related to an alteration in the 
synthesis of DA·. 
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Drugs that act by directly or indirectly stimulating 
central dopamine (DA) systems, often produce pro-
gressively greater behavioral responses with repeated 
administration. This behavioral sensitization effect 
has been demonstrated using several drugs that act as 
direct or indirect DA agonists, including cocaine, 
amphetamine and apomorphine (Castro, Abreu, 
Calzadilla and Rodriguez, 1985; Kalivas, Duffy, 
DuMars and Skinner, 1988; Mattingly, Gotsick and 
Salamanca, 1988; Reith, 1986; Robinson and Becker, 
1986; Zahniser, Peris, Dwoskin, Curella, Yasuda, 
O'Keefe and Boyson, 1988). While the acute 
behavioral effects of DA agonists are similar, 
significant behavioral differenc_es exist among these 
drugs in the development of behavioral sensitization. 
For example, chronic administration of amphetamine 
enhances amphetamine-induced stereotypy (i.e. 
repetitive sniffing, head and limb movements) and 
locomotor activity (Robinson and Becker, 1986). 
Similarly, chronic administration of cocaine enhances 
cocaine-induced stereotypy and locomotor activity 
(Kalivas et al., 1988; Reith, 1986). In contrast, 
chronic administration of apomorphine enhances 
locomotor activity but not stereotypy (Mattingly, 
Gotsick and Marin, 1988). 
•To whom correspondence should be addressed. 
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Each of the sensitization-producing DA agonists 
has a different mechanism of action on central dopa-
minergic transmission. Cocaine, _for example, en-
hances the activity of DA indirectly by inhibition of 
the uptake of dopamine (Zahniser et al., 1988). 
Amphetamine is also an indirect-acting DA agonist, 
producing its effects primarily by inducing release of 
DA (Zetterstrom, Sharp, Marsden and Ungerstedt, 
1983). In contrast, apomorphine is a direct-acting DA 
receptor agonist (Creese, Hamblin, Leff and Sibley, 
1983). The differential behavioral effects of DA ago-
nists, with chronic administration, may be related to 
the differential mechanisms of action of each of these 
drugs on DA neurotransmission. 
Much attention has been given in recent years to 
the neuropharmacological correlates of cocaine- and 
amphetamine-induced behavioral sensitization (see 
Robinson and Becker, 1986; Zahniser et al., 1988 for 
reviews). Consequently, the effects of amphetamine 
and cocaine on various indices of DA function are 
well characterized. In contrast, less is ~nown of the 
neuropharmacological effects of chronic adminis-
tration of apomorphine. Available evidence suggests 
that chronic treatment with apomorphine does not 
affect the binding of [3H]spiperone in the striatum of 
the mouse (Riffee, Wilcox, Vaughn and Smith, \982) 
but the effect of chronic treatment with apomorP,hine 
I 
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on binding sites for DA in other pathways (e.g, 
mesolimbic) has not been determined. Similarly, the 
effect of chronic treatment with apomorphine on the 
synthesis and metabolism of DA in various DA 
terminal fields is unknown. The purpose of the 
present study, therefore, was to determine the effects 
of chronic treatment with apomorphine on various 
indices of DA function in striatal and mesolimbic 
terminal fields. In three experiments, rats were in-
jected daily with a large dose of apomorphine to 
induce sensitization, using locomotor activity as a 
behavioral measure. In the first experiment, the syn-
thesis of DA in anterior striatal and mesolimbic tissue 
was assessed after acute and chronic treatment with 
apomorphine by measuring the accumulation of di-
hydroxyphenylalanine (DOPA), after administration 
of an /-aromatic amino acid decarboxylase inhibitor. 
In a second experiment, changes in levels of DA and 
3,4-dihydroxyphenylacetic acid (DOPAC) were 
measured after behavioral testing. Finally, a third 
experiment assessed the binding density of 
[3H]spiperone in striatal and mesolimbic regions after 
acute and chronic treatment with apomorphine. 
METHODS 
Subjects 
Male Wistar albino rats, experimentally naive and 
weighing between 250-300 g, were used ih each exper-
iment. All rats were housed individually, maintained 
on ad libitum food and water and a 12-hr lig~t/dark 
cycle was held constant throughout the study. All 
behavioral testing was conducted during the light 
phase of the cycle. 
Activity testing apparatus 
Measures of activity were taken in two BRS/ 
Lehigh Valley cylindrical activity drums (Model 145· 
03), which were 60 cm in diameter and 43 cm high. 
The interior of the drums was painted fiat blii.ck and 
the floor was made of 4 cm diamond wire mesh. Each 
drum was located in a separate experimental cubicle 
that was kept totally dark throughout testing. Each 
drum was equipped with two banks of three infrared 
photocells mounted of the outside of the drums. The 
photocells were approximately 12 cm apart and 
2.5 cm above the floor of the drum. The banks of 
photocells were connected to electromechanical 
counters, in an adjacent control room, by way of 
back-path eliminator diodes. Movement of the rat 
through a photocell beam sent a single pulse to the 
counters. Simultaneous pulses (i.e. pulses spaced less 
than 0.05 sec apart), such as might occur when two 
beams were broken near their intersection, were 
recorded as a single count by this method. Thus, 
activity was defined as the cumulative number of 
interruptions of photobeams per unit time. 
Locomotor activity testing and dissections 
At the beginning of each experiment, the rats were 
randomly assigned to either the apomorphine- or 
vehicle-pretreatment condition. The rats received 13 
daily subcutaneous injections of 5.0 mg/kg apomor-
phine hydrochloride (Sigma) or vehicle (0.001 N HCI), 
except in the experiment assessing the synthesis of 
DA in which only 10 daily injections were adminis-
tered. The dose injected was calculated, based on the 
weight of the salt of the drug and the volume of 
administration was held constant at 0.5 ml/kg. The 
dose of apomorphine (5.0 mg/kg) and the length of 
administration (lCl-13 days) were chosen, based on a 
previous study, which demonstrated maximum 
locomotor sensitization using these parameters 
(Mattingly et al., 1988). 
During the chronic pretreatment sessions, each rat 
was removed from its home cage, weighed and then 
injected with either apomorphine or vehicle. After the 
injection, the rats were returned to their home cage. 
Fifteen minutes later, the rats were placed in the 
activity drums and activity counts were recorded at 
10-min intervals for a total of 20 min. All rats were 
tested with an approximately 24-hr interval between 
each activity test session. 
During the final session of each experiment, one-
half of the rats in each chronic pretreatment con-
dition were randomly assigned to either the 
apomorphine- or vehicle-acute-challenge condition. 
During the drug challenge session of the DA syn-
thesis experiment, the rats were injected with either 
5.0 mg/kg apomorphine or vehicle. Fifteen minutes 
after the injection, the animals received the 
/-aromatic amino acid decarboxylase inibitor, NSD-
1015 (M-hydroxybenzylhydrazine dihydrochloride, 
100 mg/kg, i.p., Sigma) and were sacrificed 30 min 
later by rapid decapitation. The brains were rapidly 
removed and placed on a ice-cold dissection plate. 
During the challenge session with drug, of the DA 
metabolite experiment, activity measures were taken 
in order to assess the effects of acute administration 
of apomorphine on locomotor activity and levels of 
metabolites. After activity testing (20 min), the ani-
·mals were then sacrificed and ihe brains removed as 
in the DA synthesis experiment. During the drug 
challenge session of the binding experiment, each rat 
was injected with either 5.0 mg/kg apomorphine or 
vehicle and returned to its home cage. Fifteen minutes 
later, each animal was sacrificed by rapid decapi-
tation. In all the experiments, samples of striatal 
(anterior to optic chiasm) and mesolimbic (nucleus 
accumbens septi and olfactory tubercles) tissue were 
dissected, frozen on dry-ice and then stored at - 70°C 
for the assay. Tissue samples used for the assays of 
synthesis and metabolites of DA were placed in 
15 vols of 0.1 N HCI04 before freezing. 
Determination of DOPA, DA and DOPAC 
Tissue samples were thawed and sonicated with a 
microhomogenizer (Vibracell, setting 80). The hom-
ogenate was centrifuged at 40,000 g for 10 min at 4°C. 
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DOPA, DA and DOPAC using a high-pressure liquid 
chromatograph, with an electrochemical detector 
(Bioanalytical Systems, LC-304T) and a tempera-
ture-controlled (25°C) 5 µm column (Bioanalytical 
Systems, PN 6207). The mobile phase for determi-
nation of DOPA was prepared as described by Sparks 
and Slevin (1985). The mobile phase for determi-
nation of DA and DOPAC was prepared as described 
by Mayer and Shoup (1983). External standards for 
DOPA, DA and DOPAC (Sigma) were assayed daily. 
Receptor binding 
Sections of brain were thawed and homogenized, 
using a Brinkmann Polytron (5 sec, setting 6) in 
100 vols of ice-cold 50 mM Tris buffer (pH 7.4 at 
37°C). The homogenate was then centrifuged at 
40,000 g for I 0 min at 4°C. The supernatant was 
discarded and the pellet resuspended and briefly 
sonicated (Vibracell, setting 80) in an equal volume of 
Tris buffer. This washing procedure was repeated 
twice and the tissue was resuspended in a final 200 
vols of ice-cold 50 mM Tris buffer, containing 
120 mM NaCl, 5 mM KCl, 2 mM CaCl,, 1 mM 
MgS04 , IOµM pargyline and 0.1% ascorbic acid 
(pH 7.4 at 37°C). Tissue homogenates were pre-incu-
bated at 37°C for IO min and then placed on ice. After 
pre-incubation, 950 µl of tissue sample were incu-, 
bated at 37°C for 15 min with 0.4 nM [3H]spiperone 
(New England Nuclear, specific activity= 
26.8 Ci/mmol) and either 1.0 µM haloperidol or 
an equal volume of the Tris buffer with ions. In 
previous experiments, it was found that 1.0 µM 
haloperidol displaced 0.4 nM [m]spiperone from 
fresh striatum of the rat, similar to 1.0 µM ( + )-
butaclamol (unpublished observations). Fifty µM 
ketanserin (Janssen Pharmaceuticals) was added to 
all tubes to displace [3H]spiperone from 5-hydroxy-
tryptamine2 receptors (List and Seeman, 1981). Satu-
ration studies were carried out in striatal tissues, using 
six concentrations of rH]spiperone, ranging from 0.02 
to 1.0 nM. The final incubation volume was 1.0 ml. 
After incubation, the samples were returned to ice 
and filtered (Whatman GF/B glass fiber filters) under 
vacuum pressure. The filters were washed of unbound 
[3H]spiperone with two 5 ml vols of ice-cold Tris 
buffer (no ions) and placed in glass vials with 8.0 ml 
scintillation cocktail (Research Products Intl. 3a70B). 
The radioactivity was measured by liquid scintillation 
spectrometry, using a Packard 3380, with approxi-
mately 25o/o counting efficiency. Specific binding was 
defined as the difference in bound radioactivity, 
obtained in the presence and absence of haloperidol. 
All samples were assayed in duplicate. 
Analysis of data 
The pretreatment activity data were analyzed by 
mixed factor analysis of variance (ANOV A) with 
chronic pretreatment drug and acute challenge drug, 
as between groups factors and session as a repeated 
measure. The challenge treatment activity data were 
analyzed by I-tests, using the Scheffe procedure 
(family-wise error controlled at 0.05). Separate 2 x 2 
factorial ANOV As were used to analyze levels of 
DOPA, DA, DOPAC and the binding of 
[3H]spiperone for each region of the brain. 
Saturation isotherms were obtained from 
duplicated pooled tissue (i.e. n = 2), consequently, 
statistical comparisons between groups were not 
carried out. The K0 and BmaY.. values were derive9 by 
non-linear regression analysis, using the LIGAND 
software package (Munson and Rodbard, 1980). 
When a single concentration of radio ligand was used, 
the B~Ja.7,. value was estimated using the equation: 
Bm,. = B(L + K0 )/L 
In the equation, B is the amount of [3H]spiperone 
specifically bound ~t radioligand concentration L 
(Boyson, McGonigle and Molinoff, 1986). The K0 
values used in the equation were those obtained from 
the anterior striatum saturation experiments . 
RESULTS 
Locomotor activity 
Figure I presents the mean activity counts of the 
four groups for the 13 chronic pretreatment activity 
test sessions for the receptor binding experiment. The 
results from the chronic pretreatment sessions of the 
other two experiments showed similar results to 
the chronic pretreatment sessions of the binding 
experiment (data not shown). 
As may be seen in Figure I, the four groups· 
displayed comparable activity levels during the first 
session, but significant differences emerged with re-
peated testing. Chronic administration of apomor-
phine produced a progressively larger increase in 
activity with each succeeding injection (P < 0.05, 
ANOV A). This increase was asymptotic by approxi-
mately the tenth session. In contrast, the vehicle-
treated groups revealed no significant change in 
activity with the sessions. Also, the challenge drug 
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Fig. 1. Mean activity counts per 10 min block, for groups 
receiving 5.0 mg/kg apomorphine or vehicle, subdivided by 
challenge group for 13 sessions. Treatments are represented 
by chronically-administered pretreatment drug-acutely-ad-
ministered challenge drug. Drug or vehicle was administered 
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Fig. 2. Mean actiVity counts per 10 min block on day 14 
(acute challenge session) of testing. The dose of apomor-
phine used was 5.0 mg/kg. Drug or vehicle was administered 
15min before each 20min session. *P<0.05 vs chronic 
apoffiorj,hine-acute vehicle challenge and the two chronic 
morphine. In both striatal and mesoHmbic tissues, 
acute administration of apomorphine decreased .the 
accumulation of DOPA (P < 0.05, main effect of 
acute administration of drug, ANOVA). More 
important, chronic treatment with apomorphine 
resulted in a significant increase in the accumulation 
of DOPA in both_ the striatal and mesolimbic tissues 
compared to chronic treatment with vehicle 
(P < 0.05, main effect of chronic administration of 
drug, ANOV A). There was no significant interaction 
between chronic and acute treatment with drug in 
either region. 
Dopamine and DOPAC 
Table 2 presents the mean concentrations of DA 
and DOPAC. Chronic .treatment with apomorphine 
did not produce significant changes in levels of DA 
in either the striatal or mesolimbic tissues. Similarly, 
levels of DOPAC in both striatal and mesolimbic 
tissues were not affected by chronic treatment with 
apomorphine. In contrast, acute challenge inj~ctions 
of apomorphine resulted in a significant decrease 
in concentrations. of DOPAC in both regions of 
the brain (P < 0.05). This apomorphine-induced 
decrease in levels of DOPAC, however, did not differ 
for rats pretreated chronicaliy with apomorphine or 
vehicle. 
vehicle groups (I-test, Schetre•s procedure). 
groups displayed no significant differences during the 
pretreatment sessions, indicating that no inherent 
differences existed prior to the challenge test. 
Figure 2 presents the activity data from day 14 of 
the experiment on metabolites of DA. As may be seen 
from the figure, animals pretreated with apomor-
phine and challenged with apomorphine displayed 
higher levels of activity than the .other three groups 
(P < 0.05. Schefft\'s test). The latter three groups were 
not significantly different from one another in levels 
of activity. Receptor binding 
Accumulation of DOPA 
Table I presents mean accumulatiori values for 
DOPA after chronic and acute treatment with apo-
Table 3 presents the mean specific binding of 
[3H]spiperone and estimates of Bmax in striatal and 
mesolimbic tissue. As may be seen in Table 3., chronic 
treatment with apomorphine and acute challenge 
Table I. Changes in accumulation of DOPA induced by acute and chronic administration of 






Mean µg DOPA/g wet tissue weight± SEM 
Anterior striatum 
1.46 ± 0.12•.b 
1.18 ± 0.11 1 
4.14± 0.29b 
3.38 ± 0.23 
Mesolimbic region 
1.85±0.19a,b 
1.75 ± 0.22• 
3.04 ± 0.15b 
2.41 ±0.12 
"Acutely-treated apomorphine groups (Apomorphine-Apomorphine and Vehicle-
Apomorphine combined) were significantly different from acutely-treated vehicle groups 
(Apomorphine-Vehicle and Vehicle-Vehicle combined), analysis of variance, main effect of 
acute treatment with drug, P < 0.05. 
bChronically-treated apomorphine groups (Apomorphine-ApomOrphine and Apomorphine-
Vehicle combined) were significantly different from chronically-treated vehicle groups 
(Vehicle-Apomorphine and Vehicle-Vehicle combined), analysis of variance, main effect of 
chronic treatment with drug, P < 0.05. 
Table 2. Mean values for DA and DOPAC after acute and chronic treatment with apomorphine in 






Mean µg/g wet tissue weight± SEM 
Anterior striatum Mesolimbic region 
DA DOPAC DA DOPAC 
16.3 ± 1.07 2.2±0.15" 6.1±0.43 0.9 ± 0.07" 
15.5 ± 1.09 2.4±0.10" 6.2 ± 0.10 I.I ±0.07" 
15.5 ± 1.42 3.5 ±0.35 6.2 ± 0.21 1.6±0.10 
15.4 ± 1.22 3.3 ±0.32 6.2 ± 0.26 1.6±0.08 
•Acutely-treated apomorphine groUps (Apomorphine-Apomorphine and Vehicle-Aponnorphine 
combined) were significantly different from acutely-treated vehicle groups (Apomorphine-
Vehicle and Vehicle-Vehicle combined), analysis of variance, main effect of acute treatment with 
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Table 3. Specific binding of 0.4 nM [3H]spiperone after acute and chronic treatment with 
apomorphine in rats (n = 10 per group) 
Mean fmol/mg wet tissue weight± SEM 
Anterior striatum Mesolimbic region 
Treatment (chronic..:.acute) Bound B=, Bound Bmu 
Apomorphine-Apomorphine 15.9±0.7 21.9 ± 1.0 5.1±1.2 7.0± 1.6 
Vehicle-Apomorphine 15.5 ± 0.4 21.7±0.6 5.4 ± 1.2 7.6± 1.7 
Apomorphine-Vehicle 19.0 ± 0.6 24.2 ±0.8 5.0 ± 1.5 6.4 ± 1.9 
Vehicle-Vehicle 17.9 ± 0.6 23.3 ±0.8 5.7 ± 1.8 7.4 ±2.3 
Bm .. values were estimated by the equation Bm .. = B(l + K0 )/l where B.is specific [3HJspiperone 
bound and Lis the concentration of radioligand (Boyson et al., 1986). K0 viilues were obtained 
from saturation isotherms in anterior striatum. 
with apomorphine did not significantly affect the 
binding of [3H]spiperone in either the striatal or 
mesolimbic tissues (P > 0.05 in each case). 
Figure 3 presents saturation curves, Scatchard 
plots (inset), K 0 and Bmax values for striatal tissue of 
rats treated chronically with apomorphine. Scatchard 
plots were linear and subsequent LIGAND analyses 
indicated that the curves were best fit fed to a one-site 
model. Thus, within the concentration range used, 
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Fig. 3. Saturation curves and Scatchard plots (inset) for the 
binding of[3H]spiperone to anterior striatum of the rat. The 
top graph represents groups receiving a challenge of 
5.0 mg/kg apomorphine on session 14 after chronic pretreat-
ment with 5.0 mg/kg apomorphine or vehicle. The bottom 
graph represents groups receiving challenge with vehicle on 
session 14 after chronic pretreatment with 5.0 mg/kg 
apomorphine or vehicle. The KD and Bma~ values are as 
follows: Apomorphine-Apomorphine, KD = 0.15 nM; 
Brrw. = 22.39 fmol/mg wet tissue weight; Vehicle-Apornor-
phine, KD=0.16nM, Bmv..=20.72fmol/mg wet. weight; 
Apomorphine-Vehicle, K0 = 0.11 nM, Bma~ = 20.8 fmol/mg 
wet weight; Vehicle-Vehicle, KD = 0.12 nM, Bmax = 
21.96 fmol/mg wet weight. 
NP 30/2-F 
binding sites. No differences between chronically 
treated apomorphine and vehicle groups were appar-
ent in the saturation isotherms, obtained after an 
acute challenge with either apomorphine (Fig. 3, top 
panel) or vehicle (Fig. 3, bottom panel). 
DISCUSSION 
Consistent with previous studies (e.g. Castro et al., 
1985; Mattingly et al., 1988), the present results 
clearly demonstrated the development of sensitiz-
ation to apomorpine in rats, using locomotor activity 
as a behavioral measure. Moreover, as in a previous 
study (Mattingly et al., 1988), no evidence of con-
ditioned hyperactivity was observed in the present 
study, when sensitized rats were injected with vehicle 
rather than apomorphine. This latter finding suggests 
that the development of behavioral sensitization to 
apomorphine cannot be explained by conditioning 
factors alone. It should be noted, however, that 
although conditioned hyperactivity has not been ob-
served in rats sensitized to apomorphine, the poten-
tial involvement of conditioning factors cannot be 
dismissed since drug-associated contextual stimuli 
have been shown to facilitate the development of 
behavioral sensitization to apomorphine (Mattingly 
and Gotsick, 1989). 
The present study found that the accumulation of 
DOPA was increased after chronic treatment with 
apomorphine in both the striatum and the mesolim-
bic region. One possible interpretation of the ob-
served increase in synthesis of DA is that chronic 
administration of apomorphine may produce subsen-
sitivity of autoreceptors. Autoreceptors for DA ap-
pear to be part of a negative feedback loop which 
regulates the firing rate of DA neurons, as well as the 
synthesis and release of DA (Roth, 1984). By induc-
ing subsensitivity of autoreceptors, chronic adminis-
tration of apomorphine·may enhance the basal firing 
rate, release and synthesis of DA. In support of this 
subsensitivity hypothesis, the acute apomorphine-
induced inhibition of the.firing rate of DA neurons in 
the striatum and ·substantia nigra has. been shown 
to be significantly attenuated chronic treatment 
with apomorphine in large doses (Rebec and: Lee, 
1982). ' 
In contrast, behavioral experiments utilizing ad-
ministration of small doses ofapomorphine have not 
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demonstrated results consistent with the idea of an 
apomorphine-induced decrease in the sensitivity of 
autoreceptors. Administration of small doses of 
apomorphine appears to decrease locomotor activity, 
an effect proposed to be autoreceptor-specific 
(Skirboll, Grace and Bunney, 1979). Studies assessing 
the effects of chronic administration of small doses 
of apomorphine have demonstrated that both the 
ability of small doses of apomorphine to attenuate 
amphetamine-induced sensitization (Riffee, Wanek 
and Wilcox, 1987) and the ability of apomorphine to 
decrease locomotor activity (Mattingly et al., 1988) 
does not change with repeated injections. Likewise, in 
the present study, the decrease in levels of DOPAC, 
observed after acute treatment \Vith apomorphine 
was not altered by chronic treatment with 
apomorphine. The acute decrease in levels of 
DOPAC is consistent with other reports (e.g. 
Bannon and Roth, 1983; Westrink and Korf, 1976) 
and is thought to reflect stimulation of DA 
autoreceptors. Together, these behavioral and 
neurochemical results suggest that the autoreceptors 
maintain their sensitivity. An alternative explanation 
would be that a subset of autoreceptors, modulating 
synthesis of DA, as opposed to autoreceptors 
modulating release of DA, may be preferenlially 
affected by chronic administration of apomorphine 
(Wolf and Roth, 1987). However, it is also possible 
that chronic administration of apomorphine 
may produce a significant increase in synthesis 
of DA, independent of stimulation of autoreceptors, 
as recent reports have suggested that apomorphine 
may have a direct action upon tyrosine hydroxy-
lase (cf. Riffee et al., 1987; Saller and Salama, 
1986). -
The density of binding sites for DA, as measured 
by specific binding of (3H]spiperone in striatal and 
mesolimbic tissue, was not significantly affected by 
chronic administration of apomorphine. Consistent 
with this result, Riffee et al. (1982) reported no 
significant changes in the binding of [3H]spiperone in 
striatum of the mouse after chronic treatment with 
large doses of apomorphine. Likewise, chronic treat-
ment with amphetamine and cocaine do not appear 
to reliably alter the density of binding sites for DA 
(see Robinson and Becker, 1986; Zahniser et al., 
1988). Thus, apomorphine-induced sensitization, like 
amphetamine- and cocaine-induced sensitization, 
does not appear to be mediated by alterations in the 
number of postsynaptic binding sites for DA. It is, of 
course, possible that chronic treatment with apomor-
phine may result in significant changes in the D1 
receptors subtype, which may be related to the devel-
opment of behavioral sensitization. Apomorphine is 
reported to be a partial agonist at D1 sites, as well as 
a full agonist at D2 sites (Creese et al., 1983). Unfor-
tunately, the potential involvement ofD 1 sites cannot 
be determined from the present results because both 
spiperone and haloperidol bind with high affinity 
primarily to D2 receptors. 
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